


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T14:00:25Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12178961" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12178961</identifier>
    <datestamp>2025-09-05</datestamp>
    
        
        <setSpec>jcrco</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Cancer Res Clin Oncol</journal-id><journal-id journal-id-type="iso-abbrev">J Cancer Res Clin Oncol</journal-id><journal-id journal-id-type="pmc-domain-id">4687</journal-id><journal-id journal-id-type="pmc-domain">jcrco</journal-id><journal-title-group><journal-title>Journal of Cancer Research and Clinical Oncology</journal-title></journal-title-group><issn pub-type="ppub">0171-5216</issn><issn pub-type="epub">1432-1335</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12178961</article-id><article-id pub-id-type="pmcid-ver">PMC12178961.2</article-id><article-id pub-id-type="pmcaid">12178961</article-id><article-id pub-id-type="pmcaiid">12408442</article-id><article-id pub-id-type="pmid">40536732</article-id><article-id pub-id-type="doi">10.1007/s00432-025-06246-2</article-id><article-id pub-id-type="publisher-id">6246</article-id><article-version article-version-type="pmc-version">2</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>The efficacy and therapy management of nab-paclitaxel in the real-world setting for patients with advanced breast cancer &#8211; the SERAPHINA study</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Schneeweiss</surname><given-names initials="A">Andreas</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Fasching</surname><given-names initials="PA">Peter A.</given-names></name><address><email>peter.fasching@fau.de</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff16">16</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Thill</surname><given-names initials="M">Marc</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>van Mackelenbergh</surname><given-names initials="M">Marion</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Marme</surname><given-names initials="F">Frederik</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tesch</surname><given-names initials="H">Hans</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fehm</surname><given-names initials="TN">Tanja N.</given-names></name><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Park-Simon</surname><given-names initials="TW">Tjoung-Won</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>H&#228;berle</surname><given-names initials="L">Lothar</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Uhrig</surname><given-names initials="S">Sabrina</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tome</surname><given-names initials="O">Oliver</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Spall</surname><given-names initials="T">Thomas</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Theuser</surname><given-names initials="AK">Anna-Katharin</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ruebner</surname><given-names initials="M">Matthias</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Belleville</surname><given-names initials="E">Erik</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wallwiener</surname><given-names initials="D">Diethelm</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Brucker</surname><given-names initials="SY">Sara Y.</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hartkopf</surname><given-names initials="AD">Andreas D.</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04cdgtt98</institution-id><institution-id institution-id-type="GRID">grid.7497.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 0492 0584</institution-id><institution>National Center for Tumor Diseases (NCT), </institution><institution>University Hospital and German Cancer Research Center, </institution></institution-wrap>Heidelberg, Germany </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0030f2a11</institution-id><institution-id institution-id-type="GRID">grid.411668.c</institution-id><institution-id institution-id-type="ISNI">0000 0000 9935 6525</institution-id><institution>Department of Gynecology and Obstetrics, </institution><institution>Universit&#228;tsklinikum Erlangen, Friedrich- Alexander-Universit&#228;t Erlangen-N&#252;rnberg (FAU), </institution></institution-wrap>Erlangen, Germany </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05jfz9645</institution-id><institution-id institution-id-type="GRID">grid.512309.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 8340 0885</institution-id><institution>Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), </institution></institution-wrap>Erlangen, Germany </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04hd04g86</institution-id><institution-id institution-id-type="GRID">grid.491941.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 0621 6785</institution-id><institution>Department of Gynecology and Gynecological Oncology, </institution><institution>AGAPLESION MARKUS KRANKENHAUS, </institution></institution-wrap>Frankfurt, Germany </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01tvm6f46</institution-id><institution-id institution-id-type="GRID">grid.412468.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 0646 2097</institution-id><institution>Department of Gynecology and Obstetrics, </institution><institution>University Hospital Schleswig-Holstein, Campus Kiel, </institution></institution-wrap>Kiel, Germany </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05sxbyd35</institution-id><institution-id institution-id-type="GRID">grid.411778.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 2162 1728</institution-id><institution>Department of Gynecology and Obstetrics, </institution><institution>University Hospital Mannheim, </institution></institution-wrap>Mannheim, Germany </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.514056.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0636 7487</institution-id><institution>Oncology Practice, </institution><institution>Bethanien Hospital, </institution></institution-wrap>Frankfurt am Main, Germany </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/006k2kk72</institution-id><institution-id institution-id-type="GRID">grid.14778.3d</institution-id><institution-id institution-id-type="ISNI">0000 0000 8922 7789</institution-id><institution>Department of Gynecology and Obstetrics, </institution><institution>University Hospital D&#252;sseldorf, </institution></institution-wrap>D&#252;sseldorf, Germany </aff><aff id="Aff9"><label>9</label>Center for Integrated Oncology (CIO Aachen, Bonn, Cologne, D&#252;sseldorf), D&#252;sseldorf, Germany </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f2yqf98</institution-id><institution-id institution-id-type="GRID">grid.10423.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 2342 8921</institution-id><institution>Department of Gynecology and Obstetrics, </institution><institution>Hannover Medical School, </institution></institution-wrap>Hannover, Germany </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0030f2a11</institution-id><institution-id institution-id-type="GRID">grid.411668.c</institution-id><institution-id institution-id-type="ISNI">0000 0000 9935 6525</institution-id><institution>Biostatistics Unit, Department of Gynecology and Obstetrics, </institution><institution>Universit&#228;tsklinikum Erlangen, Friedrich-Alexander-Universit&#228;t Erlangen-N&#252;rnberg (FAU), </institution></institution-wrap>Erlangen, Germany </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/021wky884</institution-id><institution-id institution-id-type="GRID">grid.500034.2</institution-id><institution>Department of Gynecology and Obstetrics, </institution><institution>St. Vincentius-Kliniken gAG , </institution></institution-wrap>Karlsruhe, Germany </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="GRID">grid.519308.6</institution-id><institution>ClinSol GmbH &amp; Co KG, </institution></institution-wrap>W&#252;rzburg, Germany </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01f30wv40</institution-id><institution-id institution-id-type="GRID">grid.506347.3</institution-id><institution>Institut f&#252;r Frauengesundheit GmbH, </institution></institution-wrap>Erlangen, Germany </aff><aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00pjgxh97</institution-id><institution-id institution-id-type="GRID">grid.411544.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 0196 8249</institution-id><institution>Department of Gynecology and Obstetrics, </institution><institution>University Hospital T&#252;bingen, </institution></institution-wrap>T&#252;bingen, Germany </aff><aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f7hpc57</institution-id><institution-id institution-id-type="GRID">grid.5330.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2107 3311</institution-id><institution>Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, </institution><institution>Universit&#228;tsklinikum Erlangen, Friedrich-Alexander-Universit&#228;t Erlangen-N&#252;rnberg, </institution></institution-wrap>Universitaetsstrasse 21&#8211;23, 91054 Erlangen, Germany </aff></contrib-group><pub-date pub-type="epub"><day>19</day><month>6</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2025</year></pub-date><volume>151</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">496204</issue-id><elocation-id>192</elocation-id><history><date date-type="received"><day>13</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>10</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>19</day><month>06</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>05</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-05 00:25:44.313"><day>05</day><month>09</month><year>2025</year></date></event><event event-type="pmc-version" specific-use="live"><article-id pub-id-type="pmcaiid">12178961</article-id><article-id pub-id-type="doi">10.1007/s00432-025-06246-2</article-id><article-version>1</article-version><pub-date><day>19</day><month>06</month><year>2025</year></pub-date></event><event event-type="pmc-version" specific-use="live"><article-id pub-id-type="pmcaiid">12408442</article-id><article-id pub-id-type="doi">10.1007/s00432-025-06246-2</article-id><article-version>2</article-version><pub-date><day>19</day><month>06</month><year>2025</year></pub-date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="432_2025_Article_6246.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Chemotherapies are still widely used in advanced breast cancer, specifically in patients with HER2-negative disease. This non-interventional real-world study assessed the utilization of nab-paclitaxel in a broad patient population with advanced breast cancer.</p></sec><sec><title>Methods</title><p id="Par2">SERAPHINA (<ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT02642406">NCT02642406</ext-link>) was a single arm, non-interventional study performed in Germany. Patients were eligible if they were treated with nab-paclitaxel according to the Summary of Product Characteristics (SmPC) as indicated by their physician. Progression-free survival (PFS), overall survival (OS), safety and quality of life were evaluated. Additionally, efficacy was assessed in patient subgroups based on age, metastasis pattern, performance status and therapy line.</p></sec><sec><title>Results</title><p id="Par3">A total of 432 patients were treated with nab-paclitaxel. The majority of patients had HER2-negative disease (94.2%). Furthermore, 30.1% of patients were treated in the first line and 48.3% in the third or later therapy line. Median PFS was 6.0 months (95% CI: 5.6&#8211;6.9) and median OS was 15.3 months (95% CI: 12.5&#8211;17.5). Although no clear predictors of PFS and OS in multivariable Cox models could be identified, patients with brain metastases had the shortest PFS (3.0 months; 95% CI: 2.2&#8211;4.3). Adverse events occurred in 83.1% of patients, with high-grade adverse events being rare (&lt;&#8201;8% of patients). Quality of life did not change under therapy.</p></sec><sec><title>Conclusion</title><p id="Par4">Nab-paclitaxel is used in patients with advanced breast cancer. In this real-world, non-interventional study, prognosis was favorable and safety profile manageable, which is comparable to previous clinical trials and real-world studies.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s00432-025-06246-2.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Advanced breast cancer</kwd><kwd>Nab-paclitaxel</kwd><kwd>Chemotherapy</kwd><kwd>Real-world</kwd><kwd>Non-interventional study</kwd></kwd-group><funding-group><award-group><funding-source><institution>Universit&#228;tsklinikum Erlangen (8546)</institution></funding-source></award-group><open-access><p>Open Access funding enabled and organized by Projekt DEAL.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer-Verlag GmbH Germany, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Purpose</title><p id="Par5">In recent years, there have been major improvements in the treatment of both human epidermal growth factor receptor 2 (HER2)-negative molecular subtypes of breast cancer (i.e., triple negative breast cancer (TNBC) and hormone receptor-positive, HER2-negative (HRpos/HER2neg) breast cancer). In patients with TNBC, antibody-drug conjugates sacituzumab govitecan (Bardia et al. <xref ref-type="bibr" rid="CR2">2021</xref>) and trastuzumab deruxtecan (for HER2 low expression tumors) (Rugo et al. <xref ref-type="bibr" rid="CR28">2023</xref>) have been introduced. Additionally, the immune checkpoint inhibitors atezolizumab (in combination with nab-paclitaxel) (Schmid et al. <xref ref-type="bibr" rid="CR29">2018</xref>) and pembrolizumab (in combination with paclitaxel, nab-paclitaxel or carboplatin/gemcitabine) (Cortes et al. <xref ref-type="bibr" rid="CR6">2022</xref>) have also been approved for the first line treatment of patients with programmed death-ligand 1 (PD-L1)-positive, advanced TNBC. In patients with HRpos/HER2neg breast cancer, the introduction of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors (Hortobagyi et al. <xref ref-type="bibr" rid="CR16">2016</xref>, <xref ref-type="bibr" rid="CR15">2022</xref>; Slamon et al. <xref ref-type="bibr" rid="CR35">2019</xref>, <xref ref-type="bibr" rid="CR33">2020</xref>; Slamon et al. <xref ref-type="bibr" rid="CR34">2018</xref>; Im et al. <xref ref-type="bibr" rid="CR17">2019</xref>; Tripathy et al. <xref ref-type="bibr" rid="CR37">2018</xref>; Sledge et al. <xref ref-type="bibr" rid="CR36">2017</xref>; Goetz et al. <xref ref-type="bibr" rid="CR12">2017</xref>; Finn et al. <xref ref-type="bibr" rid="CR11">2016</xref>; Turner et al. <xref ref-type="bibr" rid="CR38">2015</xref>; Nabieva and Fasching <xref ref-type="bibr" rid="CR27">2023</xref>; Engler et al. <xref ref-type="bibr" rid="CR9">2022</xref>; Schneeweiss et al. <xref ref-type="bibr" rid="CR32">2020</xref>), and as well trastuzumab deruxtecan (for HER2 low expressing tumors) (Modi et al. <xref ref-type="bibr" rid="CR25">2022</xref>) and sacituzumab govitecan (Rugo et al. <xref ref-type="bibr" rid="CR28">2023</xref>) have changed the treatment landscape in the advanced setting. Nevertheless, chemotherapy remains the only therapeutic option after exhaustion of endocrine-based treatments, immunotherapy, antibody-drug conjugate therapy, and poly (ADP-ribose) polymerase (PARP) inhibitor therapy, and is commonly used in the second (up to 47%) and third (up to 66%) lines of therapy in patients with TNBC or HRpos/HER2neg disease (Braun et al. <xref ref-type="bibr" rid="CR4">2022</xref>).</p><p id="Par6">Therefore, classical chemotherapy is still one of the most frequently used treatment options in patients with TNBC as well as in patients with HRpos/HER2neg breast cancer. International guidelines recommend the use of single-agent chemotherapy regimens (Al Sukhun et al. <xref ref-type="bibr" rid="CR1">2024</xref>). Nevertheless, the choice of chemotherapy remains diverse and depends on prior chemotherapies, side effects and other factors. Since many patients with TNBC already receive taxane/anthracycline-based treatment regimens in the adjuvant setting (Ditsch et al. <xref ref-type="bibr" rid="CR7">2022</xref>) and <italic toggle="yes">de novo</italic> disease is uncommon in TNBC (Muller et al. <xref ref-type="bibr" rid="CR26">2022</xref>), the majority of patients with advanced TNBC have already been treated with these chemotherapies. Therefore, treatments such as platinum-based chemotherapies, bevacizumab-based regimens, eribulin-, gemcitabine- and vinorelbine-based regimens are often used in the metastatic setting when a chemotherapy is employed (Braun et al. <xref ref-type="bibr" rid="CR4">2022</xref>). In patients with advanced HRpos/HER2neg disease, taxane-based regimens are most frequently used, followed by combinations with anthracyclines, capecitabine, eribulin and other chemotherapies (Braun et al. <xref ref-type="bibr" rid="CR4">2022</xref>). Notably, many clinical trials use physicians&#8217; choice chemotherapy in the comparator arm. For example, the OlympiaD, EMBRACA, Keynote-355, ASCENT, and Destiny-B04 trials were all studies, in which the investigational treatment was compared to a chemotherapy of physicians&#8217; choice.</p><p id="Par7">All of the above-mentioned circumstances require detailed knowledge of the current use of chemotherapies. Additionally, information on efficacy and side effects could help to plan treatment sequences that optimize efficacy and minimize side effects. For patients with advanced HER2-negative disease, nab-paclitaxel may be a good option. Real-world studies can help investigate the efficacy and side effect profile of nab-paclitaxel in different patient populations, which is currently still under-researched. Therefore, the aim of this study was to evaluate the patterns of use, efficacy and toxicity of nab-paclitaxel in patients with advanced breast cancer.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design</title><p id="Par8">SERAPHINA (Safety, Efficacy And Patient Reported Outcomes of Advanced Breast Cancer Patients: Therapy Management With nab-Paclitaxel in Daily Routine; <ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT02642406">NCT02642406</ext-link>) was a single arm, non-interventional study that recruited across 76 study sites in Germany. The study was conducted in accordance with the Declaration of Helsinki and the Guidelines of the International Conference on Harmonization Good Clinical Practice (GCP). Approval of all respective ethics committees were obtained (initial approval obtained from the Ethical Committee of the Medical Faculty of the Friedrich-Alexander-Universit&#228;t Erlangen-N&#252;rnberg, Erlangen, Germany: date August 12 2015, approval number 193_15B) and all patients provided written informed consent. Patients were eligible for inclusion if they were being treated with nab-paclitaxel monotherapy according to the Summary of Product Characteristics (SmPC) as indicated by their physician. Notably, nab-paclitaxel therapy could not have been initiated more than 3 weeks prior to study entry, and patients had to have proven metastatic or locally advanced breast cancer. Patients were not allowed to participate in any other interventional study.</p></sec><sec id="Sec4"><title>Patient population</title><p id="Par9">Between December 2015 and September 2018, 454 patients were registered in the study. Five patients did not meet all inclusion/exclusion criteria and were excluded as screening failures. A further 17 patients never started nab-paclitaxel therapy and were also excluded. Ultimately, the population for which safety was reported comprised 432 patients. For efficacy analyses, 10 patients who started the nab-paclitaxel more than 21 days before study entry and 2 patients, who had no follow-up information available were additionally excluded, resulting in <italic toggle="yes">N</italic>&#8201;=&#8201;420 patients for efficacy analyses. A flow chart of the patient selection is shown in Supplementary Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>.</p></sec><sec id="Sec5"><title>Data acquisition</title><p id="Par10">Medical history, performance status, concomitant medication, and quality of life as assessed by FACT-B questionnaires were captured at study entry. This information, as well as the disease status, were assessed every three months until disease progression. Treatment was given according to the local standard. The recommended dose of nab-paclitaxel was 260 mg/m<sup>2</sup>, administered intravenously over 30&#160;min every 3 weeks. However, other treatment schedules were documented as part of the SERAPHINA study as well. Patients were followed up every three months until disease progression, death, or withdrawal of consent. The end of study was defined to be either death, withdrawal of consent or a maximum observation time of 36 months. Disease status, including disease progression, was assessed at least every three months according to the local guidelines. The database cut for this analysis was September 20, 2022.</p><p id="Par11">HER2 status and estrogen receptor (ER) and progesterone receptor (PR) expression were assessed according to the local practice standards. No central review was performed. ER and PR status were considered positive if&#8201;&#8805;&#8201;1% of the tumor cells were stained positively by immunohistochemistry. A positive HER2 status required an immunohistochemistry score of 3 or more or a positive fluorescence in situ hybridization/competitive in situ hybridization.</p><p id="Par12">Adverse events, including the severity grading, were coded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03).</p></sec><sec id="Sec6"><title>Statistical considerations</title><p id="Par13">The primary objective of this study was to describe progression-free survival (PFS) under real-life conditions. Secondary objectives included the evaluation of overall survival (OS), factors that influence PFS and OS, safety and quality of life.</p><p id="Par14">PFS was defined from the date of start of therapy to the earliest date of disease progression (distant-metastasis, local recurrence, or death from any cause) or the last date known to be progression-free. It was left-truncated for time to enter the study, if the entry was after start of therapy. OS was defined in a similar fashion.</p><p id="Par15">Survival rates with 95% confidence intervals (CIs) and median survival time were estimated using the Kaplan-Meier product limit method. The 95% CI of median survival time was computed using the method of Brookmeyer and Crowley (Brookmeyer and Crowley <xref ref-type="bibr" rid="CR5">1982</xref>).</p><p id="Par16">For each outcome (PFS, OS), a multivariable Cox regression model was fitted with the following predictors: age at diagnosis (&lt;&#8201;55 years, 55&#8211;65 years, &gt; 65 years) body mass index (BMI, in kg/m2; &lt; 20. 20&#8211;25, 25&#8211;30, &gt; 30), grading (G1/G2; G3), HR status (HRpos; HRneg), HER2 status (HER2pos; HER2neg), nodal status (pN0, pN+), metastases pattern (brain; visceral; bone; other), therapy line (first, second, third or higher). Hazard ratios with 95% CI were calculated for each predictor using this Cox regression model. Moreover, the hazard ratio for non-triple-negative versus triple-negative patients was calculated by combining the regression coefficients accordingly.</p><p id="Par17">Calculations were carried out using the R system for statistical computing (v4.2.1; R Core Team 2022)</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>Patients</title><p id="Par18">From December 2015 to September 2018, 454 patients were registered into the study, of whom 432 received nab-paclitaxel (safety population) and 420 patients had valid follow-up information available for efficacy analyses (efficacy population). A study flow chart is shown in Supplementary Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>. Patients average age was 60.0 (&#177;&#8201;11.6) years old. The majority of patients was HER2neg (94.2%) and HRpos (79.6%). Nab-paclitaxel treatment was started as a first-line therapy in 30.1% of patients, as a second-line therapy in 21.6% of patients, or as a third- or later-line therapy in 48.3% of patients. A summary of all patient characteristics is shown in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>.</p></sec><sec id="Sec9"><title>Therapy</title><p id="Par19">A total of 432 patients started nab-paclitaxel therapy. The initial planned schedule for nab-paclitaxel therapy varied among patients. A weekly schedule was planned for most patients (<italic toggle="yes">N</italic>&#8201;=&#8201;167; 38.8%), while a three-week schedule was planned for 105 patients (24.4%), and a four-week schedule (three weeks of treatment, followed by one week of rest) was planned for 149 patients (34.7%). Dose reductions were necessary in 36.6% of all patients. The mean duration of treatment was 20.9 (&#177;&#8201;45.5) weeks and the mean relative dose intensity was 0.91% (&#177;&#8201;0.44%). A summary of treatment characteristics is given in Supplementary Table 2.</p></sec><sec id="Sec10"><title>Efficacy</title><p id="Par20">The median observation time was 5.7 months for PFS and 11.2 months for OS. During this observation time, 359 disease progressions and 279 deaths occurred. Median PFS time was 6.0 months (95% CI: 5.6&#8211;6.9) and median OS time was 15.3 months (95% CI: 12.5&#8211;17.5). Survival rates are shown in Supplementary Tables 3 and Kaplan Meier Curves are shown in Figs.&#160;<xref rid="Fig1" ref-type="fig">1</xref> and <xref rid="Fig2" ref-type="fig">2</xref>. Hazard ratios for predictors of PFS and OS are shown in Table&#160;<xref rid="Tab2" ref-type="table">2</xref>. The hazard ratios for non-triple-negative versus triple-negative patients were 0.94 (95% CI: 0.52&#8211;1.70) for PFS and 0.87 (95% CI: 0.47&#8211;1.59) for OS. All median PFS and OS times and survival rates are shown in Supplementary Tables 4 and Supplementary Table 5. Median PFS and OS times were different for patients in different therapy lines and for patients with different metastases pattern. Patients in the first line had the longest median PFS (9.8 months (95% CI: 7.9&#8211;12.6)), while patients in the third or later therapy line had a median PFS time of 5.3 months (95% CI: 3.9-6.0; Supplementary Table 4). Similarly, therapy line was also associated with OS (first-line patients: median OS 25.7 months (95% CI: 20.5&#8211;37.0); third or later therapy line patients: median OS 11.4 months (95% CI: 9.7&#8211;14.2): Supplementary Table 5). Patients with brain metastases had the shortest median PFS time (3.0 months (95% CI: 2.2&#8211;4.3) vs. 6.0 month (95% CI: 5.5-7.0) for visceral metastases and 8.2 months (95% CI: 4.7&#8211;20.9) for bone metastases (Supplementary Table 4)), as well as the shortest OS time (7.6 months (95% CI: 5.8&#8211;13.2) vs. 13.1 months (95% CI: 10.9&#8211;17.1) for visceral metastases and 26.2 months (95% CI: 14.3-NA) for bone metastases; Supplementary Table 5). However, with the exception of metastasis pattern for OS, no variables that strongly influenced PFS or OS could be identified in the Cox regression model (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). Kaplan-Meier curves for PFS and OS according to age (Supplementary Fig.&#160;2), metastasis pattern (Supplementary Fig.&#160;3), performance status (Karnofsky-Index; Supplementary Fig.&#160;4) and therapy line (Supplementary Fig.&#160;5) are presented in Supplementary Materials.</p></sec><sec id="Sec11"><title>Safety</title><p id="Par21">Within the safety population (<italic toggle="yes">N</italic>&#8201;=&#8201;432), 359 patients (83.1%) were affected by adverse events, irrespective of toxicity grade. All adverse events with a frequency of 3% or higher are shown in Table&#160;<xref rid="Tab3" ref-type="table">3</xref>. The most common adverse event was peripheral neuropathy (<italic toggle="yes">N</italic>&#8201;=&#8201;192; 44.4%), followed by the lack of wellbeing (malaise; <italic toggle="yes">N</italic>&#8201;=&#8201;130; 30.1%), alopecia (<italic toggle="yes">N</italic>&#8201;=&#8201;75; 17.4%), and nausea (<italic toggle="yes">N</italic>&#8201;=&#8201;71; 16.4%). The most common high-grade adverse events (grade 3/4) were neutropenia (<italic toggle="yes">N</italic>&#8201;=&#8201;33; 7.6%), peripheral sensory neuropathy (<italic toggle="yes">N</italic>&#8201;=&#8201;19; 4.4%) and a decreased white blood cell count (<italic toggle="yes">N</italic>&#8201;=&#8201;15; 3.5%).</p></sec><sec id="Sec12"><title>Quality of life</title><p id="Par22">The results of the FACT-B questionnaire at baseline, month 3 and month 6 are shown in Table&#160;<xref rid="Tab4" ref-type="table">4</xref>. At baseline, data was available of approximately 43&#8211;45% of patients, at month 3 from approximately 32&#8211;34% of patients and at month 6 of approximately 17&#8211;18% of patients. The trial outcome index (FACT-B TOI) was maintained between the assessment timepoints at baseline, at 3 months and at 6 months (60.8, 57.7 and 60.4 respectively). All other assessment parameters of the FACT-B questionnaire were also maintained over the time (Table&#160;<xref rid="Tab4" ref-type="table">4</xref>).</p></sec></sec><sec id="Sec13"><title>Discussion</title><p id="Par23">In this non-interventional real-world study, we evaluated the use of nab-paclitaxel in a broad patient population. Nab-paclitaxel was commonly administered as an early-line therapy in breast cancer patients with HER2-negative disease. In addition, nab-paclitaxel therapy was associated with a favorable prognosis and a manageable safety profile. With the exception of metastasis pattern for OS, no variables were identified in the Cox regression analysis that influenced PFS or OS, although some differences in PFS and OS times for the metastasis pattern and therapy lines were observed.</p><p id="Par24">Results from our study are comparable to data from previous clinical trials and other real-world analyses. The first international trial to demonstrate the superiority of nab-paclitaxel over paclitaxel (using a three-week treatment schedule) showed a median PFS time of 3.3 months in the nab-paclitaxel arm (Gradishar et al. <xref ref-type="bibr" rid="CR14">2005</xref>). Most of these patients (58%) were treated in advanced therapy lines, having previously received treatment(s) in the advanced therapy setting (Gradishar et al. <xref ref-type="bibr" rid="CR14">2005</xref>). In another international study conducted in the first-line setting (Gradishar et al. <xref ref-type="bibr" rid="CR13">2009</xref>), patients were treated with a weekly treatment schedule. Here, median PFS time was 12.9 months (Gradishar et al. <xref ref-type="bibr" rid="CR13">2009</xref>). In addition, a Korean real-world analysis of 102 patients reported a median PFS time of 4.0 months, with most patients having received more than three chemotherapies in the metastatic setting (Kim et al. <xref ref-type="bibr" rid="CR18">2022</xref>). Another real-world analysis from Greece with 150 patients, of whom the majority received at least 2 or more prior therapy lines for metastatic breast cancer, described a median PFS of 7.1 months for HRpos breast cancer and 5.0 months for TNBC (Koumarianou et al. <xref ref-type="bibr" rid="CR19">2020</xref>). In a retrospective cohort study with 664 patients that was performed in the USA, patients who received nab-paclitaxel monotherapy had a median time to the next therapy or death of 6.7 months in the first line, 5.8 months in the second line and 5.3 months in the third of later line (Liang et al. <xref ref-type="bibr" rid="CR22">2015</xref>). Our non-interventional study showed a median PFS time of 9.8 months (95% CI: 7.9&#8211;12.6) in the first-line setting and 5.3 months (95% CI: 3.9-6.0) in patients in the third- or later-line setting. In subgroup analyses, metastasis pattern, performance status (Karnofsky) and therapy line were of particular interest. Although not statistically significant in the multivariable Cox model, patients in earlier therapy lines had a better outcome than those in later lines. Furthermore, patients with brain metastases or a lower performance status had a less favorable prognosis. This is in line with many studies, which have been published in real-world studies (Laakmann et al. <xref ref-type="bibr" rid="CR20">2020</xref>; Witzel et al. <xref ref-type="bibr" rid="CR39">2018</xref>).</p><p id="Par25">In the large randomized nab-paclitaxel trials (Gradishar et al. <xref ref-type="bibr" rid="CR14">2005</xref>, <xref ref-type="bibr" rid="CR13">2009</xref>), severe neutropenia (grade 3/4) was reported in 25&#8211;44% of patients. This is significantly higher than the 7.6% reported in this real-world study. However, febrile neutropenia that would have resulted in a serious medical condition was not reported. Therefore, the higher incidence in the clinical trials may result from more frequent blood testing for neutropenia. Peripheral sensory neuropathy was also more commonly reported in the clinical trials. Grade 3/4 neuropathy was seen in 8&#8211;17% of patients (Gradishar et al. <xref ref-type="bibr" rid="CR14">2005</xref>, <xref ref-type="bibr" rid="CR13">2009</xref>). In our study, this adverse event was observed in 4.4% of patients, which may be due to underreporting. Other real-world analyses have also reported lower numbers of severe febrile neutropenia, ranging between 0.7 and 5% (Bernardo et al. <xref ref-type="bibr" rid="CR3">2017</xref>; Koumarianou et al. <xref ref-type="bibr" rid="CR19">2020</xref>; Marschner et al. <xref ref-type="bibr" rid="CR23">2018</xref>).</p><p id="Par26">While nab-paclitaxel remains one of several chemotherapy options for patients with HRpos/HER2neg disease when endocrine treatments have been exhausted, the introduction of immune checkpoint inhibitors has changed the therapy landscape of patients with advanced TNBC. Atezolizumab and pembrolizumab have been approved for the treatment of PD-L1 positive breast cancer (Cortes et al. <xref ref-type="bibr" rid="CR6">2022</xref>; Schmid et al. <xref ref-type="bibr" rid="CR29">2018</xref>). In both the Impassion130 and Keynote-355 trials, immune checkpoint inhibitor was used as the combination partner for chemotherapy. After the negative results of the Impassion131 study (Miles et al.<xref ref-type="bibr" rid="CR24"> 2021</xref>), in which solvent paclitaxel was used as a combination partner, it was discussed whether the immunological properties of the combination partner (solvent paclitaxel vs. nab-paclitaxel) might be the reason for the negative results. However, in the Keynote-355 study, both chemotherapies were allowed and there was no difference in efficacy when using either nab-paclitaxel or solvent paclitaxel. Also in the neoadjuvant setting in which pembrolizumab is approved in combination with a platinum/anthracycline/paclitaxel-containing chemotherapy (Schmid et al. <xref ref-type="bibr" rid="CR30">2022</xref>; Schmid et al. <xref ref-type="bibr" rid="CR31">2020</xref>), there is data that supports the efficacy in combination with nab-paclitaxel (Fasching et al. <xref ref-type="bibr" rid="CR10">2023</xref>). Taken together, nab-paclitaxel might be a favorable combination partner for immune checkpoint inhibitors in the advanced therapy setting. Whether nab-paclitaxel or more advanced antibody-drug conjugates such as sacituzumab govitecan are the better choice for HER2-negative metastatic breast cancer remains unclear, although the ongoing ASCENT-03 and ASCENT-04 trials may provide more clarity.</p><p id="Par27">Our study has several strengths and limitations. With 432 patients treated with nab-paclitaxel, our study is one of the larger real-world studies providing survival estimates. The favorable prognosis in our study is noteworthy because it is higher than previously reported in both clinical trials and real-world studies. A systematic comparison of the treatment effects in 21 randomized controlled trials and the corresponding effects in real-world datasets could show that real-world treatment benefits were 16% lower than those reported in randomized controlled trials with surrogate endpoints such as PFS (Lakdawalla et al. <xref ref-type="bibr" rid="CR21">2017</xref>). Therefore, our study may be biased toward a population with a more favorable prognosis. However, we performed a comprehensive analysis of patient subgroups to better assess the prognosis across the variability of the patient population. Further studies with more samples that examine additional predictors (e.g., prior treatments, genetic markers, inflammatory indices) using advanced statistical methods (e.g., machine learning approaches) could help identify significant predictors for PFS and OS. Adverse event rates are also lower than in the clinical trials. This is a concern in many registries (Dreyer et al. <xref ref-type="bibr" rid="CR8">2008</xref>). Underreporting is the main reason for this issue. In clinical trials, more frequent diagnostic procedures could lead to the higher adverse event rate in those studies. While this is necessary during drug development to accurately capture all safety concerns, these frequent diagnostic measures may not be necessary in real-world studies. Consequently, real-world studies, such as the present one, may be appropriate to assess the incidence of adverse events that are relevant to the actual management of therapy in routine clinical practice.</p><p id="Par28">In conclusion, we could show that nab-paclitaxel is used in patients with advanced breast cancer. Furthermore, nab-paclitaxel therapy was associated with a favorable prognosis and manageable safety profile in this real-world non-interventional study.</p><p id="Par29">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Patient and disease characteristics (efficacy population, <italic toggle="yes">N</italic>&#8201;=&#8201;420)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Characteristics</th><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">mean (SD) or <italic toggle="yes">N</italic> (%)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age (years)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">60.0 (11.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">BMI (kg/m<sup>2</sup>)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">26.0 (5.3)</td></tr><tr><td align="left" colspan="1" rowspan="1">Grading at diagnosis</td><td align="left" colspan="1" rowspan="1">G1</td><td char="." align="char" colspan="1" rowspan="1">15 (4.4)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">G2</td><td char="." align="char" colspan="1" rowspan="1">196 (57.3)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">G3</td><td char="." align="char" colspan="1" rowspan="1">131 (38.3)</td></tr><tr><td align="left" colspan="1" rowspan="1">HR status at diagnosis</td><td align="left" colspan="1" rowspan="1">HRpos</td><td char="." align="char" colspan="1" rowspan="1">77 (20.4)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">HRneg</td><td char="." align="char" colspan="1" rowspan="1">301 (79.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">HER2 status at diagnosis</td><td align="left" colspan="1" rowspan="1">HER2neg</td><td char="." align="char" colspan="1" rowspan="1">323 (94.2)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">HER2pos</td><td char="." align="char" colspan="1" rowspan="1">20 (5.8)</td></tr><tr><td align="left" colspan="1" rowspan="1">Nodal status at diagnosis</td><td align="left" colspan="1" rowspan="1">pN0</td><td char="." align="char" colspan="1" rowspan="1">112 (38.0)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">pN+</td><td char="." align="char" colspan="1" rowspan="1">153 (51.9)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">pNX</td><td char="." align="char" colspan="1" rowspan="1">30 (10.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">Metastasis at diagnosis</td><td align="left" colspan="1" rowspan="1">cM0</td><td char="." align="char" colspan="1" rowspan="1">261 (75.0)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">cM1</td><td char="." align="char" colspan="1" rowspan="1">87 (25.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Metastasis pattern</td><td align="left" colspan="1" rowspan="1">Brain</td><td char="." align="char" colspan="1" rowspan="1">33 (8.3)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Visceral</td><td char="." align="char" colspan="1" rowspan="1">260 (65.2)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Bone</td><td char="." align="char" colspan="1" rowspan="1">25 (6.3)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Others</td><td char="." align="char" colspan="1" rowspan="1">81 (20.3)</td></tr><tr><td align="left" colspan="1" rowspan="1">Karnofsky Index</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;70%</td><td char="." align="char" colspan="1" rowspan="1">26 (6.8)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">70 &#8722;&#8201;100%</td><td char="." align="char" colspan="1" rowspan="1">356 (93.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">(neo)adjuvant chemotherapy</td><td align="left" colspan="1" rowspan="1">no</td><td char="." align="char" colspan="1" rowspan="1">43 (16.7)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">yes</td><td char="." align="char" colspan="1" rowspan="1">215 (83.3)</td></tr><tr><td align="left" colspan="1" rowspan="1">(neo)adjuvant endocrine therapy</td><td align="left" colspan="1" rowspan="1">no</td><td char="." align="char" colspan="1" rowspan="1">340 (94.2)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">yes</td><td char="." align="char" colspan="1" rowspan="1">21 (5.8)</td></tr><tr><td align="left" colspan="1" rowspan="1">Treatment line</td><td align="left" colspan="1" rowspan="1">first</td><td char="." align="char" colspan="1" rowspan="1">123 (30.1)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">second</td><td char="." align="char" colspan="1" rowspan="1">88 (21.6)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">third or more</td><td char="." align="char" colspan="1" rowspan="1">197 (48.3)</td></tr></tbody></table><table-wrap-foot><p>[HR: hormone receptor: HER2: human epidermal growth factor receptor 2; pos: positive; neg: negative; SD: standard deviation; BMI: body mass index]</p></table-wrap-foot></table-wrap>
</p><p id="Par30">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Multivariable Cox regression model for progression-free survival and overall survival (survival analysis population, <italic toggle="yes">N</italic>&#8201;=&#8201;420)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Predictor</th><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">PFS<break/>hazard ratio<break/>(95% CI)</th><th align="left" colspan="1" rowspan="1">OS<break/>hazard ratio<break/>(95% CI)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age (year)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;55</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">-<sup>1</sup></td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">55&#8211;65</td><td align="left" colspan="1" rowspan="1">1.22 (0.80, 1.85)</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8805;&#8201;66</td><td align="left" colspan="1" rowspan="1">1.40 (0.95, 2.05)</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">BMI (kg/m<sup>2</sup>)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;20</td><td align="left" colspan="1" rowspan="1">1.35 (0.68, 2.68)</td><td align="left" colspan="1" rowspan="1">1.30 (0.61, 2.77)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">20&#8211;25</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">Reference</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">25&#8211;30</td><td align="left" colspan="1" rowspan="1">1.30 (0.86, 1.97)</td><td align="left" colspan="1" rowspan="1">1.06 (0.67, 1.67)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&gt;&#8201;30</td><td align="left" colspan="1" rowspan="1">1.36 (0.84, 2.19)</td><td align="left" colspan="1" rowspan="1">1.11 (0.66, 1.86)</td></tr><tr><td align="left" colspan="1" rowspan="1">Grading</td><td align="left" colspan="1" rowspan="1">G1/G2</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">Reference</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">G3</td><td align="left" colspan="1" rowspan="1">1.07 (0.74, 1.54)</td><td align="left" colspan="1" rowspan="1">1.08 (0.71, 1.63)</td></tr><tr><td align="left" colspan="1" rowspan="1">HR status</td><td align="left" colspan="1" rowspan="1">HRneg</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">Reference</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">HRpos</td><td align="left" colspan="1" rowspan="1">0.81 (0.52, 1.26)</td><td align="left" colspan="1" rowspan="1">0.72 (0.44, 1.18)</td></tr><tr><td align="left" colspan="1" rowspan="1">HER2 status</td><td align="left" colspan="1" rowspan="1">HER2neg</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">Reference</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">HER2pos</td><td align="left" colspan="1" rowspan="1">1.35 (0.62, 2.92)</td><td align="left" colspan="1" rowspan="1">1.45 (0.65, 3.20)</td></tr><tr><td align="left" colspan="1" rowspan="1">Nodal status</td><td align="left" colspan="1" rowspan="1">pN0</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">Reference</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">pN+</td><td align="left" colspan="1" rowspan="1">1.43 (0.98, 2.09)</td><td align="left" colspan="1" rowspan="1">1.30 (0.86, 1.98)</td></tr><tr><td align="left" colspan="1" rowspan="1">Metastasis pattern</td><td align="left" colspan="1" rowspan="1">Brain</td><td align="left" colspan="1" rowspan="1">1.81 (0.86, 3.79)</td><td align="left" colspan="1" rowspan="1">2.23 (1.07, 4.66)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Visceral</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">Reference</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Bone</td><td align="left" colspan="1" rowspan="1">0.48 (0.21, 1.09)</td><td align="left" colspan="1" rowspan="1">0.66 (0.28, 1.56)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Others</td><td align="left" colspan="1" rowspan="1">0.61 (0.40, 0.95)</td><td align="left" colspan="1" rowspan="1">0.47 (0.28, 0.78)</td></tr><tr><td align="left" colspan="1" rowspan="1">Therapy line</td><td align="left" colspan="1" rowspan="1">first</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">Reference</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">second</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">1.19 (0.70, 2.03)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">third or higher</td><td align="left" colspan="1" rowspan="1">.</td><td align="left" colspan="1" rowspan="1">1.35 (0.84, 2.17)</td></tr></tbody></table><table-wrap-foot><p><sup>1</sup> The proportional hazards assumptions are not met for &#8220;age at diagnosis&#8221;-categories for overall survival. Age at diagnosis was used instead as a stratification variable</p><p><sup>2</sup> The proportional hazards assumptions are not met for &#8220;therapy line&#8221;-categories for progression-free survival. Therapy line was used instead as a stratification variable</p><p>
<italic toggle="yes">[HR: hormone receptor: HER2: human epidermal growth factor receptor 2; pos: positive; neg: negative; BMI: body mass index: PFS: progression-free survival; OS: overall survival]</italic>
</p></table-wrap-foot></table-wrap>
</p><p id="Par31">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Reported adverse events with a frequency over 3% (all grades) in the safety population (<italic toggle="yes">N</italic>&#8201;=&#8201;432)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">CTCAE Term</th><th align="left" colspan="1" rowspan="1">All Grades <italic toggle="yes">N</italic> (%)</th><th align="left" colspan="1" rowspan="1">Grade 3/4<break/><italic toggle="yes">N</italic> (%)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Peripheral sensory neuropathy</td><td align="left" colspan="1" rowspan="1">192 (44.4)</td><td align="left" colspan="1" rowspan="1">19 (4.4)</td></tr><tr><td align="left" colspan="1" rowspan="1">Malaise</td><td align="left" colspan="1" rowspan="1">130 (30.1)</td><td align="left" colspan="1" rowspan="1">6 (1.4)</td></tr><tr><td align="left" colspan="1" rowspan="1">Alopecia</td><td align="left" colspan="1" rowspan="1">75 (17.4)</td><td align="left" colspan="1" rowspan="1">6 (1.4)</td></tr><tr><td align="left" colspan="1" rowspan="1">Nausea</td><td align="left" colspan="1" rowspan="1">71 (16.4)</td><td align="left" colspan="1" rowspan="1">3 (0.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">Diarrhea</td><td align="left" colspan="1" rowspan="1">63 (14.6)</td><td align="left" colspan="1" rowspan="1">1 (0.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">Neutrophil count decreased</td><td align="left" colspan="1" rowspan="1">57 (13.2)</td><td align="left" colspan="1" rowspan="1">33 (7.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">Dyspnea</td><td align="left" colspan="1" rowspan="1">54 (12.5)</td><td align="left" colspan="1" rowspan="1">1 (0.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">Mucositis oral</td><td align="left" colspan="1" rowspan="1">43 (10)</td><td align="left" colspan="1" rowspan="1">2 (0.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">Anemia</td><td align="left" colspan="1" rowspan="1">41 (9.5)</td><td align="left" colspan="1" rowspan="1">11 (2.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">Rhinitis infective</td><td align="left" colspan="1" rowspan="1">38 (8.8)</td><td align="left" colspan="1" rowspan="1">0 (0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Arthralgia</td><td align="left" colspan="1" rowspan="1">36 (8.3)</td><td align="left" colspan="1" rowspan="1">0 (0)</td></tr><tr><td align="left" colspan="1" rowspan="1">White blood cell decreased</td><td align="left" colspan="1" rowspan="1">36 (8.3)</td><td align="left" colspan="1" rowspan="1">15 (3.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">Dysgeusia</td><td align="left" colspan="1" rowspan="1">31 (7.2)</td><td align="left" colspan="1" rowspan="1">0 (0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Constipation</td><td align="left" colspan="1" rowspan="1">30 (6.9)</td><td align="left" colspan="1" rowspan="1">1 (0.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">Edema limbs</td><td align="left" colspan="1" rowspan="1">28 (6.5)</td><td align="left" colspan="1" rowspan="1">0 (0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Anorexia</td><td align="left" colspan="1" rowspan="1">27 (6.2)</td><td align="left" colspan="1" rowspan="1">2 (0.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">Nail discoloration</td><td align="left" colspan="1" rowspan="1">27 (6.2)</td><td align="left" colspan="1" rowspan="1">0 (0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Dizziness</td><td align="left" colspan="1" rowspan="1">26 (6)</td><td align="left" colspan="1" rowspan="1">1 (0.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">Bone pain</td><td align="left" colspan="1" rowspan="1">24 (5.6)</td><td align="left" colspan="1" rowspan="1">0 (0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Epistaxis</td><td align="left" colspan="1" rowspan="1">21 (4.9)</td><td align="left" colspan="1" rowspan="1">0 (0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Headache</td><td align="left" colspan="1" rowspan="1">21 (4.9)</td><td align="left" colspan="1" rowspan="1">0 (0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Myalgia</td><td align="left" colspan="1" rowspan="1">21 (4.9)</td><td align="left" colspan="1" rowspan="1">0 (0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Vomiting</td><td align="left" colspan="1" rowspan="1">21 (4.9)</td><td align="left" colspan="1" rowspan="1">1 (0.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">Rash maculo-papular</td><td align="left" colspan="1" rowspan="1">20 (4.6)</td><td align="left" colspan="1" rowspan="1">0 (0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Investigations - Other, specify</td><td align="left" colspan="1" rowspan="1">18 (4.2)</td><td align="left" colspan="1" rowspan="1">3 (0.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">Pain in extremity</td><td align="left" colspan="1" rowspan="1">18 (4.2)</td><td align="left" colspan="1" rowspan="1">0 (0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Cough</td><td align="left" colspan="1" rowspan="1">17 (3.9)</td><td align="left" colspan="1" rowspan="1">1 (0.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">Pain</td><td align="left" colspan="1" rowspan="1">17 (3.9)</td><td align="left" colspan="1" rowspan="1">2 (0.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">Stomach pain</td><td align="left" colspan="1" rowspan="1">16 (3.7)</td><td align="left" colspan="1" rowspan="1">0 (0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Lymphedema</td><td align="left" colspan="1" rowspan="1">14 (3.2)</td><td align="left" colspan="1" rowspan="1">0 (0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Skin and subcutaneous tissue disorders - Other, specify</td><td align="left" colspan="1" rowspan="1">14 (3.2)</td><td align="left" colspan="1" rowspan="1">0 (0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Alanine aminotransferase increased</td><td align="left" colspan="1" rowspan="1">13 (3)</td><td align="left" colspan="1" rowspan="1">0 (0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Nail loss</td><td align="left" colspan="1" rowspan="1">13 (3)</td><td align="left" colspan="1" rowspan="1">0 (0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Platelet count decreased</td><td align="left" colspan="1" rowspan="1">13 (3)</td><td align="left" colspan="1" rowspan="1">4 (0.9)</td></tr><tr><td align="left" colspan="1" rowspan="1">Urinary tract infection</td><td align="left" colspan="1" rowspan="1">13 (3)</td><td align="left" colspan="1" rowspan="1">0 (0)</td></tr></tbody></table><table-wrap-foot><p>[CTCAE: Common Terminology Criteria for Adverse Events]</p></table-wrap-foot></table-wrap>
</p><p id="Par32">
<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Quality of life assessment, as assessed with the FACT-B questionnaire, showing mean scores and standard deviation in efficacy population (<italic toggle="yes">N</italic>&#8201;=&#8201;420 patients)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="2" rowspan="1">Baseline</th><th align="left" colspan="2" rowspan="1">Month 3</th><th align="left" colspan="2" rowspan="1">Month 6</th></tr><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Response<break/><italic toggle="yes">N</italic> (%)</th><th align="left" colspan="1" rowspan="1">Score<break/>Mean (SD)</th><th align="left" colspan="1" rowspan="1">Response<break/><italic toggle="yes">N</italic> (%)</th><th align="left" colspan="1" rowspan="1">Score<break/>Mean (SD)</th><th align="left" colspan="1" rowspan="1">Response<break/><italic toggle="yes">N</italic> (%)</th><th align="left" colspan="1" rowspan="1">Score<break/>Mean (SD)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">FACT-B TOI</td><td char="." align="char" colspan="1" rowspan="1">189 (43.8)</td><td char="." align="char" colspan="1" rowspan="1">60.8 (15.8)</td><td char="." align="char" colspan="1" rowspan="1">142 (32.9)</td><td char="." align="char" colspan="1" rowspan="1">57.7 (16.4)</td><td char="." align="char" colspan="1" rowspan="1">76 (17.6)</td><td char="." align="char" colspan="1" rowspan="1">60.4 (14.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">FACT-B total score</td><td char="." align="char" colspan="1" rowspan="1">185 (42.8)</td><td char="." align="char" colspan="1" rowspan="1">98.7 (21.0)</td><td char="." align="char" colspan="1" rowspan="1">140 (32.4)</td><td char="." align="char" colspan="1" rowspan="1">94.8 (22.0)</td><td char="." align="char" colspan="1" rowspan="1">74 (17.1)</td><td char="." align="char" colspan="1" rowspan="1">99.0 (21.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">Physical well-being</td><td char="." align="char" colspan="1" rowspan="1">193 (44.7)</td><td char="." align="char" colspan="1" rowspan="1">19.3 (6.1)</td><td char="." align="char" colspan="1" rowspan="1">147 (34.0)</td><td char="." align="char" colspan="1" rowspan="1">18.4 (6.3)</td><td char="." align="char" colspan="1" rowspan="1">76 (17.6)</td><td char="." align="char" colspan="1" rowspan="1">18.9 (5.4)</td></tr><tr><td align="left" colspan="1" rowspan="1">Social well-being</td><td char="." align="char" colspan="1" rowspan="1">188 (43.5)</td><td char="." align="char" colspan="1" rowspan="1">22.0 (5.4)</td><td char="." align="char" colspan="1" rowspan="1">146 (33.8)</td><td char="." align="char" colspan="1" rowspan="1">21.3 (5.5)</td><td char="." align="char" colspan="1" rowspan="1">75 (17.4)</td><td char="." align="char" colspan="1" rowspan="1">21.8 (5.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">Emotional well-being</td><td char="." align="char" colspan="1" rowspan="1">191 (44.2)</td><td char="." align="char" colspan="1" rowspan="1">15.6 (4.7)</td><td char="." align="char" colspan="1" rowspan="1">145 (33.6)</td><td char="." align="char" colspan="1" rowspan="1">15.8 (5.0)</td><td char="." align="char" colspan="1" rowspan="1">76 (17.6)</td><td char="." align="char" colspan="1" rowspan="1">16.6 (5.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Functional well-being</td><td char="." align="char" colspan="1" rowspan="1">193 (44.7)</td><td char="." align="char" colspan="1" rowspan="1">15.7 (6.1)</td><td char="." align="char" colspan="1" rowspan="1">148 (34.3)</td><td char="." align="char" colspan="1" rowspan="1">14.5 (6.0)</td><td char="." align="char" colspan="1" rowspan="1">77 (17.8)</td><td char="." align="char" colspan="1" rowspan="1">15.6 (5.9)</td></tr><tr><td align="left" colspan="1" rowspan="1">Breast Cancer Subscale</td><td char="." align="char" colspan="1" rowspan="1">193 (44.7)</td><td char="." align="char" colspan="1" rowspan="1">26.0 (6.5)</td><td char="." align="char" colspan="1" rowspan="1">143 (33.1)</td><td char="." align="char" colspan="1" rowspan="1">24.8 (6.9)</td><td char="." align="char" colspan="1" rowspan="1">77 (17.8)</td><td char="." align="char" colspan="1" rowspan="1">25.8 (6.5)</td></tr></tbody></table><table-wrap-foot><p>[SD: standard deviation]</p></table-wrap-foot></table-wrap>
</p><p id="Par33">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Progression-free survival in the efficacy population (<italic toggle="yes">N</italic>&#8201;=&#8201;420)</p></caption><graphic id="d33e1634" position="float" orientation="portrait" xlink:href="432_2025_6246_Fig1_HTML.jpg"/></fig>
</p><p id="Par34">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Overall survival in the efficacy population (<italic toggle="yes">N</italic>&#8201;=&#8201;420)</p></caption><graphic id="d33e1648" position="float" orientation="portrait" xlink:href="432_2025_6246_Fig2_HTML.jpg"/></fig>
</p></sec><sec id="Sec14" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xlink:href="432_2025_6246_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This study was conducted as an investigator-initiated trial. It was partially funded by Celgene. The funding entity did not have any influence on how the study was conducted or the content of this manuscript.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Conceptualization: DW, SYB, ADH; Data curation: SU, PAF; Formal analysis: LH; Funding acquisition: PAF, EB; Investigation: AS, PAF, MT, MvM, FM, HT, TNF, TWP-S, OT, TS, DW, SYB, ADH; Project administration: A-KT, MR, EB; Supervision: DW, ADH; Visualization: LH, PAF; Writing &#8211; original draft: PAF, EB; Writing &#8211; review &amp; editing: AS, PAF, MT, MvM, FM, HT, TNF, TWP-S, LH, SU, OT, TS, A-KT, MR, EB, DW, SYB, ADH.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open Access funding enabled and organized by Projekt DEAL. This study was conducted as an investigator-initiated trial. It was partially funded by Celgene. The funding entity did not have any influence on how the study was conducted or the content of this manuscript.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar2"><title>Ethics approval</title><p id="Par35">SERAPHINA (Safety, Efficacy And Patient Reported Outcomes of Advanced Breast Cancer Patients: Therapy Management With nab-Paclitaxel in Daily Routine; <ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT02642406">NCT02642406</ext-link>) was a single arm, non-interventional study that recruited across 76 study sites in Germany. The study was conducted in accordance with the Declaration of Helsinki and the Guidelines of the International Conference on Harmonization Good Clinical Practice (GCP). Approval of all respective ethics committees were obtained (initial approval obtained from the Ethical Committee of the Medical Faculty of the Friedrich-Alexander-Universit&#228;t Erlangen-N&#252;rnberg, Erlangen, Germany: date August 12 2015, approval number 193_15B) and all patients provided written informed consent.</p></notes><notes id="FPar3"><title>Consent t<italic toggle="yes">o</italic> participate</title><p id="Par36">All study participants provided written informed consent before study inclusion.</p></notes><notes id="FPar4"><title>Consent to publish</title><p id="Par37">Not applicable. Personalized or identifiable data is not part of this manuscript.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par38">A.S. received research grants from Celgene, Roche, honoraria from Amgen, AstraZeneca, Aurikamed, Bayer, Celgene, Clinsol, Connectmedica, Gilead, GSK, I-MED, Lilly, MCI Deutschland, Metaplan, MSD, Nanostring, Novartis, Onkowissen.de, Promedicis, Pfizer, Pierre Fabre, Roche, Seagen, Streamedup, Teva, Tesaro, Thieme and travel support from Celgene, Pfizer, Roche. P.A.F. reports personal fees from Novartis, grants from Biontech, personal fees from Pfizer, personal fees from Daiichi-Sankyo, personal fees from Astra Zeneca, personal fees from Eisai, personal fees from Merck Sharp &amp; Dohme, grants from Cepheid, personal fees from Lilly, personal fees from Pierre Fabre, personal fees from SeaGen, personal fees from Roche, personal fees from Hexal, personal fees from Agendia, personal fees from Gilead. M.T. has participated on advisory boards for AstraZeneca, Celgene, Clovis, Daiichi Sanyo, Eisai, Gilead Science, Gr&#252;nenthal, GSK, Lilly, MSD, Novartis, Organon, Pfizer, Pierre-Fabre, Seagen and Roche and has received honoraria for lectures from Amgen, Aurikamed, Celgene, Clovis, Daiichi Sankyo, Eisai, GSK, Lilly, MSD, Roche, Novartis, Organon, Pfizer, Seagen, Exact Sciences, Viatris, Vifor and AstraZeneca and has received trial funding by Exact Sciences and Endomag Manuscript support was done by Amgen, ClearCut, pfm medical, Roche, Servier, Vifor. H.T. received honoraria from Novartis, Roche, Celgene, TEVA, Pfizer, Astra Zeneca and travel support from Roche, Celgene and Pfizer. T.N.F. has participated on advisory boards for Amgen, Daiichi Sankyo, Novartis, Pfizer, and Roche and has received honoraria for lectures from Amgen, Celgene, Daiichi Sankyo, Roche, Novartis and Pfizer. T.W.P.-S. received honoraria from Roche, AstraZeneca, Daiichi-Sankyo, Eisai, Exact Sciences, Gilead, GSK, MSD, NCO, Novartis, Onkowissen, ONKO-Internetportal, Pfizer, Roche, Seagen, and Thieme. T.S. received honoraria from Gilead, Ipsen, Sanofi, Sandoz, SunPharma, AstraZeneca, Novartis, Hexal, BMS, Lilly, Pfizer, Roche, MSD, BBraun and onkowissen.de for clinical research management and/or medical education activities. E.B. received honoraria from Gilead, Ipsen, Sanofi, Sandoz, SunPharma, AstraZeneca, Novartis, Hexal, BMS, Lilly, Pfizer, Roche, MSD, BBraun and onkowissen.de for clinical research management and/or medical education activities. S.Y.B. received honoraria from Roche, Novartis, Pfizer, AstraZeneca, Lilly, MSD and Hologic. A.D.H. received speaker and consultancy honoraria from AstraZeneca, Genomic Health, Roche, Novartis, Celgene, Lilly, MSD, Eisai, Teva, Tesaro, Daiichi-Sankyo, Hexal and Pfizer. All remaining authors have nothing to disclose.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><mixed-citation publication-type="other">Al Sukhun S, Temin S, Barrios CH, Antone NZ, Guerra YC, Chavez-MacGregor M, Chopra R, Danso MA, Gomez HL, Homian NM, Kandil A, Kithaka B, Koczwara B, Moy B, Nakigudde G, Petracci FE, Rugo HS, El NS, Saghir and B. K. Arun (2024) Systemic treatment of patients with metastatic breast cancer: ASCO resource-stratified guideline. JCO Glob Oncol 10:e2300285<pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/GO.23.00285</pub-id><pub-id pub-id-type="pmcid">PMC10793992</pub-id><pub-id pub-id-type="pmid">38206277</pub-id></mixed-citation></ref><ref id="CR2"><mixed-citation publication-type="other">Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortes J, O&#8217;Shaughnessy J, Dieras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM H. S. Rugo, and Ascent Clinical Trial Investigators (2021) Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med 384:1529&#8211;1541</mixed-citation></ref><ref id="CR3"><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernardo</surname><given-names>A</given-names></name><name name-style="western"><surname>Palumbo</surname><given-names>R</given-names></name><name name-style="western"><surname>Pedersini</surname><given-names>R</given-names></name><name name-style="western"><surname>Rota Caremoli</surname><given-names>E</given-names></name><name name-style="western"><surname>Gambaro</surname><given-names>AR</given-names></name><name name-style="western"><surname>Ferzi</surname><given-names>A</given-names></name><name name-style="western"><surname>Riva</surname><given-names>F</given-names></name><name name-style="western"><surname>Grasso</surname><given-names>D</given-names></name><name name-style="western"><surname>Danova</surname><given-names>M</given-names></name><name name-style="western"><surname>Tarenzi</surname><given-names>E</given-names></name><name name-style="western"><surname>Torri</surname><given-names>V</given-names></name><name name-style="western"><surname>Cazzaniga</surname><given-names>ME</given-names></name></person-group><article-title>Nab-Paclitaxel in advanced HER2-negative breast Cancer patients: efficacy and safety beyond clinical trials</article-title><source>Clin Breast Cancer</source><year>2017</year><volume>17</volume><fpage>433</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1016/j.clbc.2017.03.004</pub-id><pub-id pub-id-type="pmid">28366406</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Bernardo A, Palumbo R, Pedersini R, Rota Caremoli E, Gambaro AR, Ferzi A, Riva F, Grasso D, Danova M, Tarenzi E, Torri V, Cazzaniga ME (2017) Nab-Paclitaxel in advanced HER2-negative breast Cancer patients: efficacy and safety beyond clinical trials. Clin Breast Cancer 17:433&#8211;440<pub-id pub-id-type="pmid">28366406</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clbc.2017.03.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><mixed-citation publication-type="other">Braun M, Stoetzer O, Salat C, Borchardt J, Reichelt R, Kuske A (2022) Current therapy landscape of advanced HER2 negative breast cancer in pateints in a network of office based internistic oncologists and gynecologic oncologists in Germany. Deutscher Krebskongress:Abstract 306</mixed-citation></ref><ref id="CR5"><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brookmeyer</surname><given-names>R</given-names></name><name name-style="western"><surname>Crowley</surname><given-names>J</given-names></name></person-group><article-title>A Confidence-Interval for the median Survival-Time</article-title><source>Biometrics</source><year>1982</year><volume>38</volume><fpage>29</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.2307/2530286</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Brookmeyer R, Crowley J (1982) A confidence-interval for the median survival-time. Biometrics 38:29&#8211;41</mixed-citation></citation-alternatives></ref><ref id="CR6"><mixed-citation publication-type="other">Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W P. Schmid, and Keynote- Investigators (2022) Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med 387:217&#8211;226</mixed-citation></ref><ref id="CR7"><mixed-citation publication-type="other">Ditsch N, W&#246;cke A, Untch M, Jackisch C, Albert US, Banys-Paluchowski M, Bauerfeind I, Blohmer JU, Budach W, Dall P, Fallenberg EM, Fasching PA, Fehm TN, Friedrich M, Gerber B, Gluz O, Harbeck N, Heil J, Huober J, Kreipe HH, Krug D, K&#252;hn T, K&#252;mmel S, Kolberg-Liedtke C, Loibl S, L&#252;ftner D, Lux MP, Maass N, Mundhenke C, Nitz U, Park-Simon TW, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Sch&#252;tz F, Sinn HP, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Witzel I, M&#252;ller V, Janni W, Thill M (2022) AGO recommendations for the diagnosis and treatment of patients with early breast cancer:Update 2022 Breast Care</mixed-citation></ref><ref id="CR8"><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dreyer</surname><given-names>NA</given-names></name><name name-style="western"><surname>Sheth</surname><given-names>N</given-names></name><name name-style="western"><surname>Trontell</surname><given-names>A</given-names></name><name name-style="western"><surname>Gliklich</surname><given-names>RE</given-names></name></person-group><article-title>Good practices for handling adverse events detected through patient registries</article-title><source>Drug Inform J</source><year>2008</year><volume>42</volume><fpage>421</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1177/009286150804200502</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Dreyer NA, Sheth N, Trontell A, Gliklich RE (2008) Good practices for handling adverse events detected through patient registries Drug Inform J 42:421428</mixed-citation></citation-alternatives></ref><ref id="CR9"><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Engler</surname><given-names>T</given-names></name><name name-style="western"><surname>Fasching</surname><given-names>PA</given-names></name><name name-style="western"><surname>Luftner</surname><given-names>D</given-names></name><name name-style="western"><surname>Hartkopf</surname><given-names>AD</given-names></name><name name-style="western"><surname>Muller</surname><given-names>V</given-names></name><name name-style="western"><surname>Kolberg</surname><given-names>HC</given-names></name><name name-style="western"><surname>Hadji</surname><given-names>P</given-names></name><name name-style="western"><surname>Tesch</surname><given-names>H</given-names></name><name name-style="western"><surname>Haberle</surname><given-names>L</given-names></name><name name-style="western"><surname>Ettl</surname><given-names>J</given-names></name><name name-style="western"><surname>Wallwiener</surname><given-names>M</given-names></name><name name-style="western"><surname>Beckmann</surname><given-names>MW</given-names></name><name name-style="western"><surname>Hein</surname><given-names>A</given-names></name><name name-style="western"><surname>Belleville</surname><given-names>E</given-names></name><name name-style="western"><surname>Uhrig</surname><given-names>S</given-names></name><name name-style="western"><surname>Wimberger</surname><given-names>P</given-names></name><name name-style="western"><surname>Hielscher</surname><given-names>C</given-names></name><name name-style="western"><surname>Kurbacher</surname><given-names>CM</given-names></name><name name-style="western"><surname>Wuerstlein</surname><given-names>R</given-names></name><name name-style="western"><surname>Untch</surname><given-names>M</given-names></name><name name-style="western"><surname>Taran</surname><given-names>FA</given-names></name><name name-style="western"><surname>Enzinger</surname><given-names>HM</given-names></name><name name-style="western"><surname>Krabisch</surname><given-names>P</given-names></name><name name-style="western"><surname>Welslau</surname><given-names>M</given-names></name><name name-style="western"><surname>Maasberg</surname><given-names>M</given-names></name><name name-style="western"><surname>Hempel</surname><given-names>D</given-names></name><name name-style="western"><surname>Lux</surname><given-names>MP</given-names></name><name name-style="western"><surname>Michel</surname><given-names>LL</given-names></name><name name-style="western"><surname>Janni</surname><given-names>W</given-names></name><name name-style="western"><surname>Wallwiener</surname><given-names>D</given-names></name><name name-style="western"><surname>Brucker</surname><given-names>SY</given-names></name><name name-style="western"><surname>Fehm</surname><given-names>TN</given-names></name><name name-style="western"><surname>Schneeweiss</surname><given-names>A</given-names></name></person-group><article-title>Implementation of CDK4/6 inhibitors and its influence on the treatment landscape of advanced breast Cancer Patients - Data from the Real-World registry PRAEGNANT</article-title><source>Geburtshilfe Frauenheilkd</source><year>2022</year><volume>82</volume><fpage>1055</fpage><lpage>1067</lpage><pub-id pub-id-type="doi">10.1055/a-1880-0087</pub-id><pub-id pub-id-type="pmid">36186151</pub-id><pub-id pub-id-type="pmcid">PMC9525148</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Engler T, Fasching PA, Luftner D, Hartkopf AD, Muller V, Kolberg HC, Hadji P, Tesch H, Haberle L, Ettl J, Wallwiener M, Beckmann MW, Hein A, Belleville E, Uhrig S, Wimberger P, Hielscher C, Kurbacher CM, Wuerstlein R, Untch M, Taran FA, Enzinger HM, Krabisch P, Welslau M, Maasberg M, Hempel D, Lux MP, Michel LL, Janni W, Wallwiener D, Brucker SY, Fehm TN, Schneeweiss A (2022) Implementation of CDK4/6 inhibitors and its influence on the treatment landscape of advanced breast Cancer Patients - Data from the Real-World registry PRAEGNANT. Geburtshilfe Frauenheilkd 82:1055&#8211;1067<pub-id pub-id-type="pmid">36186151</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/a-1880-0087</pub-id><pub-id pub-id-type="pmcid">PMC9525148</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fasching</surname><given-names>PA</given-names></name><name name-style="western"><surname>Hein</surname><given-names>A</given-names></name><name name-style="western"><surname>Kolberg</surname><given-names>HC</given-names></name><name name-style="western"><surname>Haberle</surname><given-names>L</given-names></name><name name-style="western"><surname>Uhrig</surname><given-names>S</given-names></name><name name-style="western"><surname>Rubner</surname><given-names>M</given-names></name><name name-style="western"><surname>Belleville</surname><given-names>E</given-names></name><name name-style="western"><surname>Hack</surname><given-names>CC</given-names></name><name name-style="western"><surname>Fehm</surname><given-names>TN</given-names></name><name name-style="western"><surname>Janni</surname><given-names>W</given-names></name><name name-style="western"><surname>Hartmann</surname><given-names>A</given-names></name><name name-style="western"><surname>Erber</surname><given-names>R</given-names></name><name name-style="western"><surname>Theuser</surname><given-names>AK</given-names></name><name name-style="western"><surname>Brucker</surname><given-names>SY</given-names></name><name name-style="western"><surname>Hartkopf</surname><given-names>AD</given-names></name><name name-style="western"><surname>Untch</surname><given-names>M</given-names></name></person-group><article-title>Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer - A single-arm phase II trial (NeoImmunoboost, AGO-B-041)</article-title><source>Eur J Cancer</source><year>2023</year><volume>184</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2023.01.001</pub-id><pub-id pub-id-type="pmid">36871424</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Fasching PA, Hein A, Kolberg HC, Haberle L, Uhrig S, Rubner M, Belleville E, Hack CC, Fehm TN, Janni W, Hartmann A, Erber R, Theuser AK, Brucker SY, Hartkopf AD, Untch M (2023) Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer - A single-arm phase II trial (NeoImmunoboost, AGO-B-041). Eur J Cancer 184:1&#8211;9<pub-id pub-id-type="pmid">36871424</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2023.01.001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finn</surname><given-names>RS</given-names></name><name name-style="western"><surname>Martin</surname><given-names>M</given-names></name><name name-style="western"><surname>Rugo</surname><given-names>HS</given-names></name><name name-style="western"><surname>Jones</surname><given-names>S</given-names></name><name name-style="western"><surname>Im</surname><given-names>SA</given-names></name><name name-style="western"><surname>Gelmon</surname><given-names>K</given-names></name><name name-style="western"><surname>Harbeck</surname><given-names>N</given-names></name><name name-style="western"><surname>Lipatov</surname><given-names>ON</given-names></name><name name-style="western"><surname>Walshe</surname><given-names>JM</given-names></name><name name-style="western"><surname>Moulder</surname><given-names>S</given-names></name><name name-style="western"><surname>Gauthier</surname><given-names>E</given-names></name><name name-style="western"><surname>Lu</surname><given-names>DR</given-names></name><name name-style="western"><surname>Randolph</surname><given-names>S</given-names></name><name name-style="western"><surname>Dieras</surname><given-names>V</given-names></name><name name-style="western"><surname>Slamon</surname><given-names>DJ</given-names></name></person-group><article-title>Palbociclib and letrozole in advanced breast Cancer</article-title><source>N Engl J Med</source><year>2016</year><volume>375</volume><fpage>1925</fpage><lpage>1936</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1607303</pub-id><pub-id pub-id-type="pmid">27959613</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Dieras V, Slamon DJ (2016) Palbociclib and letrozole in advanced breast Cancer. N Engl J Med 375:1925&#8211;1936<pub-id pub-id-type="pmid">27959613</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1607303</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><mixed-citation publication-type="other">Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Tredan O, Chen SC, Manso L, Freedman OC, Garnica Jaliffe G, Forrester T, Frenzel M, Barriga S, Smith IC, Bourayou N, Di Leo A (2017) MONARCH 3:Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol 35:3638&#8211;3646<pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2017.75.6155</pub-id><pub-id pub-id-type="pmid">28968163</pub-id></mixed-citation></ref><ref id="CR14"><mixed-citation publication-type="other">Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M (2005) and J. O&#8217;Shaughnessy. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer&#8217; J Clin Oncol 23:7794&#8211;&#8201;803<pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2005.04.937</pub-id><pub-id pub-id-type="pmid">16172456</pub-id></mixed-citation></ref><ref id="CR13"><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gradishar</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Krasnojon</surname><given-names>D</given-names></name><name name-style="western"><surname>Cheporov</surname><given-names>S</given-names></name><name name-style="western"><surname>Makhson</surname><given-names>AN</given-names></name><name name-style="western"><surname>Manikhas</surname><given-names>GM</given-names></name><name name-style="western"><surname>Clawson</surname><given-names>A</given-names></name><name name-style="western"><surname>Bhar</surname><given-names>P</given-names></name></person-group><article-title>Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><fpage>3611</fpage><lpage>3619</lpage><pub-id pub-id-type="doi">10.1200/JCO.2008.18.5397</pub-id><pub-id pub-id-type="pmid">19470941</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, Bhar P (2009) Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 27:3611&#8211;3619<pub-id pub-id-type="pmid">19470941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2008.18.5397</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><mixed-citation publication-type="other">Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, Andre F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O&#8217;Shaughnessy J (2016) Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer N Engl J Med 375: 1738-48<pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1609709</pub-id><pub-id pub-id-type="pmid">27717303</pub-id></mixed-citation></ref><ref id="CR15"><mixed-citation publication-type="other">Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, Campone M, Petrakova K, Winer EP, Janni W, Conte P, Cameron DA, Andr&#233; F, Arteaga CL, Zarate JP, Chakravartty A, Taran T, Le Gac F, Serra P, O&#8217;Shaughnessy J (2022) Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer, N Engl J Med 386:942&#8211;&#8201;50<pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2114663</pub-id><pub-id pub-id-type="pmid">35263519</pub-id></mixed-citation></ref><ref id="CR17"><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Im</surname><given-names>SA</given-names></name></person-group><article-title>Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer</article-title><source>N Engl J Med</source><year>2019</year><volume>381</volume><fpage>307</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1903765</pub-id><pub-id pub-id-type="pmid">31166679</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Im SA, Lu YS, Bardia A, Harbeck N, Colleoni M, Franke F, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva-Vazquez R, Jung KH, Chakravartty A, Hughes G, Gounaris I, Rodriguez-Lorenc K, Taran T, Hurvitz S, Tripathy D (2019) &#8216;Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer&#8217;. N Engl J Med 381:307&#8211;16. 10.1056/NEJMoa1903765<pub-id pub-id-type="pmid">31166679</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1903765</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>JS</given-names></name><name name-style="western"><surname>Suh</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Lee</surname><given-names>DW</given-names></name><name name-style="western"><surname>Woo</surname><given-names>GU</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SH</given-names></name><name name-style="western"><surname>Ryu</surname><given-names>HS</given-names></name><name name-style="western"><surname>Lee</surname><given-names>KH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>TY</given-names></name><name name-style="western"><surname>Han</surname><given-names>SW</given-names></name><name name-style="western"><surname>Park</surname><given-names>SY</given-names></name><name name-style="western"><surname>Park</surname><given-names>IA</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JH</given-names></name><name name-style="western"><surname>Im</surname><given-names>SA</given-names></name></person-group><article-title>A Real-World efficacy of Nab-Paclitaxel monotherapy in metastatic breast Cancer</article-title><source>Cancer Res Treat</source><year>2022</year><volume>54</volume><fpage>488</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.4143/crt.2021.394</pub-id><pub-id pub-id-type="pmid">34412194</pub-id><pub-id pub-id-type="pmcid">PMC9016319</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Kim JS, Suh KJ, Lee DW, Woo GU, Kim M, Kim SH, Ryu HS, Lee KH, Kim TY, Han SW, Park SY, Park IA, Kim JH, Im SA (2022) A Real-World efficacy of Nab-Paclitaxel monotherapy in metastatic breast Cancer. Cancer Res Treat 54:488&#8211;496<pub-id pub-id-type="pmid">34412194</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4143/crt.2021.394</pub-id><pub-id pub-id-type="pmcid">PMC9016319</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koumarianou</surname><given-names>A</given-names></name><name name-style="western"><surname>Makrantonakis</surname><given-names>P</given-names></name><name name-style="western"><surname>Zagouri</surname><given-names>F</given-names></name><name name-style="western"><surname>Papadimitriou</surname><given-names>C</given-names></name><name name-style="western"><surname>Christopoulou</surname><given-names>A</given-names></name><name name-style="western"><surname>Samantas</surname><given-names>E</given-names></name><name name-style="western"><surname>Christodoulou</surname><given-names>C</given-names></name><name name-style="western"><surname>Psyrri</surname><given-names>A</given-names></name><name name-style="western"><surname>Bafaloukos</surname><given-names>D</given-names></name><name name-style="western"><surname>Aravantinos</surname><given-names>G</given-names></name><name name-style="western"><surname>Papakotoulas</surname><given-names>P</given-names></name><name name-style="western"><surname>Baka</surname><given-names>S</given-names></name><name name-style="western"><surname>Andreadis</surname><given-names>C</given-names></name><name name-style="western"><surname>Alexopoulos</surname><given-names>A</given-names></name><name name-style="western"><surname>Bompolaki</surname><given-names>I</given-names></name><name name-style="western"><surname>Kampoli</surname><given-names>K</given-names></name><name name-style="western"><surname>Liori</surname><given-names>S</given-names></name><name name-style="western"><surname>Karvounis</surname><given-names>K</given-names></name><name name-style="western"><surname>Ardavanis</surname><given-names>A</given-names></name></person-group><article-title>ABREAST: a prospective, real-world study on the effect of nab-paclitaxel treatment on clinical outcomes and quality of life of patients with metastatic breast cancer</article-title><source>Breast Cancer Res Treat</source><year>2020</year><volume>182</volume><fpage>85</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1007/s10549-020-05677-4</pub-id><pub-id pub-id-type="pmid">32418045</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Koumarianou A, Makrantonakis P, Zagouri F, Papadimitriou C, Christopoulou A, Samantas E, Christodoulou C, Psyrri A, Bafaloukos D, Aravantinos G, Papakotoulas P, Baka S, Andreadis C, Alexopoulos A, Bompolaki I, Kampoli K, Liori S, Karvounis K, Ardavanis A (2020) ABREAST: a prospective, real-world study on the effect of nab-paclitaxel treatment on clinical outcomes and quality of life of patients with metastatic breast cancer. Breast Cancer Res Treat 182:85&#8211;96<pub-id pub-id-type="pmid">32418045</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10549-020-05677-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><mixed-citation publication-type="other">Laakmann E, Witzel I, Neunhoffer T, Weide R, Schmidt M, Park-Simon TW, Mobus V, Mundhenke C, Polasik A, Lubbe K, Hesse T, Riecke K, Thill M, Fasching PA, Denkert C, Fehm T, Nekljudova V, Rey J, Loibl S, Muller V (2020) Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases Cancers (Basel) 12<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers12102787</pub-id><pub-id pub-id-type="pmcid">PMC7600746</pub-id><pub-id pub-id-type="pmid">32998430</pub-id></mixed-citation></ref><ref id="CR21"><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lakdawalla</surname><given-names>DN</given-names></name><name name-style="western"><surname>Shafrin</surname><given-names>J</given-names></name><name name-style="western"><surname>Hou</surname><given-names>N</given-names></name><name name-style="western"><surname>Peneva</surname><given-names>D</given-names></name><name name-style="western"><surname>Vine</surname><given-names>S</given-names></name><name name-style="western"><surname>Park</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Brookmeyer</surname><given-names>R</given-names></name><name name-style="western"><surname>Figlin</surname><given-names>RA</given-names></name></person-group><article-title>Predicting Real-World effectiveness of Cancer therapies using overall survival and Progression-Free survival from clinical trials: empirical evidence for the ASCO value framework</article-title><source>Value Health</source><year>2017</year><volume>20</volume><fpage>866</fpage><lpage>875</lpage><pub-id pub-id-type="doi">10.1016/j.jval.2017.04.003</pub-id><pub-id pub-id-type="pmid">28712615</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Lakdawalla DN, Shafrin J, Hou N, Peneva D, Vine S, Park J, Zhang J, Brookmeyer R, Figlin RA (2017) Predicting real-world effectiveness of cancer therapies using overall survival and progression-free survival from clinical trials: empirical evidence for the ASCO value framework. Value Health 20:866&#8211;875<pub-id pub-id-type="pmid">28712615</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jval.2017.04.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>C</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Fraser</surname><given-names>CD</given-names></name><name name-style="western"><surname>Ko</surname><given-names>A</given-names></name><name name-style="western"><surname>Corzo</surname><given-names>D</given-names></name><name name-style="western"><surname>Enger</surname><given-names>C</given-names></name><name name-style="western"><surname>Patt</surname><given-names>D</given-names></name></person-group><article-title>The treatment patterns, efficacy, and safety of Nab ((R))-paclitaxel for the treatment of metastatic breast cancer in the united states: results from health insurance claims analysis</article-title><source>BMC Cancer</source><year>2015</year><volume>15</volume><fpage>1019</fpage><pub-id pub-id-type="doi">10.1186/s12885-015-2027-x</pub-id><pub-id pub-id-type="pmid">26714468</pub-id><pub-id pub-id-type="pmcid">PMC4696215</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Liang C, Li L, Fraser CD, Ko A, Corzo D, Enger C, Patt D (2015) The treatment patterns, efficacy, and safety of Nab ((R))-paclitaxel for the treatment of metastatic breast cancer in the united states: results from health insurance claims analysis. BMC Cancer 15:1019<pub-id pub-id-type="pmid">26714468</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-015-2027-x</pub-id><pub-id pub-id-type="pmcid">PMC4696215</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><mixed-citation publication-type="other">Marschner N, Salat C, Soling U, Hansen R, Grebhardt S, Harde J, Nusch A, Potthoff K (2018) Prospective, multicenter study in 697 patients with metastatic breast cancer treated with nab-Paclitaxel. Clin Breast Cancer 18:e1323&#8211;e37 Final effectiveness and safety results of NABUCCO: real-world data from a noninterventional<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clbc.2018.07.010</pub-id><pub-id pub-id-type="pmid">30100104</pub-id></mixed-citation></ref><ref id="CR24"><mixed-citation publication-type="other">Miles D, Gligorov J, Andre F, Cameron D, Schneeweiss A, Barrios C, Xu B, Wardley A, Kaen D, Andrade L, Semiglazov V, Reinisch M, Patel S, Patre M, Morales L, Patel SL, Kaul M, Barata T, O&#8217;Shaughnessy J and I (2021) Mpassion131 investigators &#8216;primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer&#8217; Ann Oncol 32:994&#8211;1004<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2021.05.801</pub-id><pub-id pub-id-type="pmid">34219000</pub-id></mixed-citation></ref><ref id="CR25"><mixed-citation publication-type="other">Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA (2022) Trastuzumab deruxtecan in previously treated HER2-Low advanced breast cancer N Engl J Med</mixed-citation></ref><ref id="CR26"><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muller</surname><given-names>V</given-names></name><name name-style="western"><surname>Hein</surname><given-names>A</given-names></name><name name-style="western"><surname>Hartkopf</surname><given-names>AD</given-names></name><name name-style="western"><surname>Fasching</surname><given-names>PA</given-names></name><name name-style="western"><surname>Kolberg</surname><given-names>HC</given-names></name><name name-style="western"><surname>Hadji</surname><given-names>P</given-names></name><name name-style="western"><surname>Tesch</surname><given-names>H</given-names></name><name name-style="western"><surname>Haberle</surname><given-names>L</given-names></name><name name-style="western"><surname>Ettl</surname><given-names>J</given-names></name><name name-style="western"><surname>Luftner</surname><given-names>D</given-names></name><name name-style="western"><surname>Wallwiener</surname><given-names>M</given-names></name><name name-style="western"><surname>Beckmann</surname><given-names>MW</given-names></name><name name-style="western"><surname>Schneeweiss</surname><given-names>A</given-names></name><name name-style="western"><surname>Belleville</surname><given-names>E</given-names></name><name name-style="western"><surname>Uhrig</surname><given-names>S</given-names></name><name name-style="western"><surname>Wimberger</surname><given-names>P</given-names></name><name name-style="western"><surname>Hielscher</surname><given-names>C</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>J</given-names></name><name name-style="western"><surname>Wurmthaler</surname><given-names>LA</given-names></name><name name-style="western"><surname>Kurbacher</surname><given-names>CM</given-names></name><name name-style="western"><surname>Wuerstlein</surname><given-names>R</given-names></name><name name-style="western"><surname>Untch</surname><given-names>M</given-names></name><name name-style="western"><surname>Janni</surname><given-names>W</given-names></name><name name-style="western"><surname>Taran</surname><given-names>FA</given-names></name><name name-style="western"><surname>Lux</surname><given-names>MP</given-names></name><name name-style="western"><surname>Wallwiener</surname><given-names>D</given-names></name><name name-style="western"><surname>Brucker</surname><given-names>SY</given-names></name><name name-style="western"><surname>Fehm</surname><given-names>TN</given-names></name><name name-style="western"><surname>Michel</surname><given-names>LL</given-names></name></person-group><article-title>Occurrence and characteristics of patients with de Novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry</article-title><source>Eur J Cancer</source><year>2022</year><volume>172</volume><fpage>13</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2022.05.015</pub-id><pub-id pub-id-type="pmid">35728342</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Muller V, Hein A, Hartkopf AD, Fasching PA, Kolberg HC, Hadji P, Tesch H, Haberle L, Ettl J, Luftner D, Wallwiener M, Beckmann MW, Schneeweiss A, Belleville E, Uhrig S, Wimberger P, Hielscher C, Meyer J, Wurmthaler LA, Kurbacher CM, Wuerstlein R, Untch M, Janni W, Taran FA, Lux MP, Wallwiener D, Brucker SY, Fehm TN, Michel LL (2022) Occurrence and characteristics of patients with de Novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry Eur J Cancer 172:13&#8211;21<pub-id pub-id-type="pmid">35728342</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2022.05.015</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><mixed-citation publication-type="other">Nabieva N, Fasching PA (2023) &#8216;CDK4/6 Inhibitors-Overcoming endocrine resistance is the standard in patients with hormone receptor-positive breast cancer&#8217; cancers (Basel), 15<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers15061763</pub-id><pub-id pub-id-type="pmcid">PMC10046117</pub-id><pub-id pub-id-type="pmid">36980649</pub-id></mixed-citation></ref><ref id="CR28"><mixed-citation publication-type="other">Rugo HS, Bardia A, Marme F, Cortes J, Schmid P, Loirat D, Tredan O, Ciruelos E, Dalenc F, Gomez Pardo P, Jhaveri KL, Delaney R, Valdez T, Wang H, Motwani M, Yoon OK, Verret W, Tolaney SM (2023) &#8216;Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02):a randomised, open-label, multicentre, phase 3 trial&#8217; Lancet<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(23)01245-X</pub-id><pub-id pub-id-type="pmid">37633306</pub-id></mixed-citation></ref><ref id="CR29"><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmid</surname><given-names>P</given-names></name><name name-style="western"><surname>Adams</surname><given-names>S</given-names></name><name name-style="western"><surname>Rugo</surname><given-names>HS</given-names></name><name name-style="western"><surname>Schneeweiss</surname><given-names>A</given-names></name><name name-style="western"><surname>Barrios</surname><given-names>CH</given-names></name><name name-style="western"><surname>Iwata</surname><given-names>H</given-names></name><name name-style="western"><surname>Dieras</surname><given-names>V</given-names></name><name name-style="western"><surname>Hegg</surname><given-names>R</given-names></name><name name-style="western"><surname>Im</surname><given-names>SA</given-names></name><name name-style="western"><surname>Shaw Wright</surname><given-names>G</given-names></name><name name-style="western"><surname>Henschel</surname><given-names>V</given-names></name><name name-style="western"><surname>Molinero</surname><given-names>L</given-names></name><name name-style="western"><surname>Chui</surname><given-names>SY</given-names></name><name name-style="western"><surname>Funke</surname><given-names>R</given-names></name><name name-style="western"><surname>Husain</surname><given-names>A</given-names></name><name name-style="western"><surname>Winer</surname><given-names>EP</given-names></name><name name-style="western"><surname>Loi</surname><given-names>S</given-names></name><name name-style="western"><surname>Emens</surname><given-names>LA</given-names></name></person-group><article-title>Atezolizumab and Nab-Paclitaxel in advanced Triple-Negative breast Cancer</article-title><source>N Engl J Med</source><year>2018</year><volume>379</volume><fpage>2108</fpage><lpage>2121</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1809615</pub-id><pub-id pub-id-type="pmid">30345906</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA (2018) Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast Cancer N Engl J Med 379:2108&#8211;2121and I. Mpassion130 trial investigators<pub-id pub-id-type="pmid">30345906</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1809615</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><mixed-citation publication-type="other">Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R J. O&#8217;Shaughnessy, and Keynote- Investigators. (2020) &#8216;Pembrolizumab for early triple-negative breast cancer&#8217; N Engl J Med 382:810&#8211;821</mixed-citation></ref><ref id="CR30"><mixed-citation publication-type="other">Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, K&#252;mmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O&#8217;Shaughnessy J and KEYNOTE-522 Investigators. (2022) &#8216;Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer&#8217; N Engl J Med</mixed-citation></ref><ref id="CR32"><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneeweiss</surname><given-names>A</given-names></name><name name-style="western"><surname>Ettl</surname><given-names>J</given-names></name><name name-style="western"><surname>Luftner</surname><given-names>D</given-names></name><name name-style="western"><surname>Beckmann</surname><given-names>MW</given-names></name><name name-style="western"><surname>Belleville</surname><given-names>E</given-names></name><name name-style="western"><surname>Fasching</surname><given-names>PA</given-names></name><name name-style="western"><surname>Fehm</surname><given-names>TN</given-names></name><name name-style="western"><surname>Geberth</surname><given-names>M</given-names></name><name name-style="western"><surname>Haberle</surname><given-names>L</given-names></name><name name-style="western"><surname>Hadji</surname><given-names>P</given-names></name><name name-style="western"><surname>Hartkopf</surname><given-names>AD</given-names></name><name name-style="western"><surname>Hielscher</surname><given-names>C</given-names></name><name name-style="western"><surname>Huober</surname><given-names>J</given-names></name><name name-style="western"><surname>Ruckhaberle</surname><given-names>E</given-names></name><name name-style="western"><surname>Janni</surname><given-names>W</given-names></name><name name-style="western"><surname>Kolberg</surname><given-names>HC</given-names></name><name name-style="western"><surname>Kurbacher</surname><given-names>CM</given-names></name><name name-style="western"><surname>Klein</surname><given-names>E</given-names></name><name name-style="western"><surname>Lux</surname><given-names>MP</given-names></name><name name-style="western"><surname>Muller</surname><given-names>V</given-names></name><name name-style="western"><surname>Nabieva</surname><given-names>N</given-names></name><name name-style="western"><surname>Overkamp</surname><given-names>F</given-names></name><name name-style="western"><surname>Tesch</surname><given-names>H</given-names></name><name name-style="western"><surname>Laakmann</surname><given-names>E</given-names></name><name name-style="western"><surname>Taran</surname><given-names>FA</given-names></name><name name-style="western"><surname>Seitz</surname><given-names>J</given-names></name><name name-style="western"><surname>Thomssen</surname><given-names>C</given-names></name><name name-style="western"><surname>Untch</surname><given-names>M</given-names></name><name name-style="western"><surname>Wimberger</surname><given-names>P</given-names></name><name name-style="western"><surname>Wuerstlein</surname><given-names>R</given-names></name><name name-style="western"><surname>Volz</surname><given-names>B</given-names></name><name name-style="western"><surname>Wallwiener</surname><given-names>D</given-names></name><name name-style="western"><surname>Wallwiener</surname><given-names>M</given-names></name><name name-style="western"><surname>Brucker</surname><given-names>SY</given-names></name></person-group><article-title>Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany</article-title><source>Breast</source><year>2020</year><volume>54</volume><fpage>88</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.breast.2020.08.011</pub-id><pub-id pub-id-type="pmid">32956934</pub-id><pub-id pub-id-type="pmcid">PMC7509062</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Schneeweiss A, Ettl J, Luftner D, Beckmann MW, Belleville E, Fasching PA, Fehm TN, Geberth M, Haberle L, Hadji P, Hartkopf AD, Hielscher C, Huober J, Ruckhaberle E, Janni W, Kolberg HC, Kurbacher CM, Klein E, Lux MP, Muller V, Nabieva N, Overkamp F, Tesch H, Laakmann E, Taran FA, Seitz J, Thomssen C, Untch M, Wimberger P, Wuerstlein R, Volz B, Wallwiener D, Wallwiener M, Brucker SY (2020) initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. Breast 54:88&#8211;95<pub-id pub-id-type="pmid">32956934</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.breast.2020.08.011</pub-id><pub-id pub-id-type="pmcid">PMC7509062</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slamon</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Neven</surname><given-names>P</given-names></name><name name-style="western"><surname>Chia</surname><given-names>S</given-names></name><name name-style="western"><surname>Fasching</surname><given-names>PA</given-names></name><name name-style="western"><surname>De Laurentiis</surname><given-names>M</given-names></name><name name-style="western"><surname>Im</surname><given-names>SA</given-names></name><name name-style="western"><surname>Petrakova</surname><given-names>K</given-names></name><name name-style="western"><surname>Bianchi</surname><given-names>GV</given-names></name><name name-style="western"><surname>Esteva</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Mart&#237;n</surname><given-names>M</given-names></name><name name-style="western"><surname>Nusch</surname><given-names>A</given-names></name><name name-style="western"><surname>Sonke</surname><given-names>GS</given-names></name><name name-style="western"><surname>De la Cruz-Merino</surname><given-names>L</given-names></name><name name-style="western"><surname>Beck</surname><given-names>JT</given-names></name><name name-style="western"><surname>Pivot</surname><given-names>X</given-names></name><name name-style="western"><surname>Sondhi</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chakravartty</surname><given-names>A</given-names></name><name name-style="western"><surname>Rodriguez-Lorenc</surname><given-names>K</given-names></name><name name-style="western"><surname>Jerusalem</surname><given-names>G</given-names></name></person-group><article-title>Overall survival results from the phase 3 MONALEESA-3 study of fulvestrant&#8201;&#177;&#8201;ribociclib in postmenopausal patients with HR+/HER2&#8211;&#8201;Advanced breast Cancer</article-title><source>Ann Oncol</source><year>2019</year><volume>30</volume><issue>suppl5</issue><fpage>v851</fpage><lpage>v934</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdz394</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Mart&#237;n M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Sondhi M, Wang Y, Chakravartty A, Rodriguez-Lorenc K, Jerusalem G (2019) Overall survival results from the phase 3 MONALEESA-3 study of fulvestrant&#8201;&#177;&#8201;ribociclib in postmenopausal patients with HR+/HER2&#8211;&#8201;Advanced breast cancer Ann Oncol 30(suppl5):v851&#8211;v934. 10.1093/annonc/mdz394</mixed-citation></citation-alternatives></ref><ref id="CR33"><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slamon</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Neven</surname><given-names>P</given-names></name><name name-style="western"><surname>Chia</surname><given-names>S</given-names></name><name name-style="western"><surname>Fasching</surname><given-names>PA</given-names></name><name name-style="western"><surname>De Laurentiis</surname><given-names>M</given-names></name><name name-style="western"><surname>Im</surname><given-names>SA</given-names></name><name name-style="western"><surname>Petrakova</surname><given-names>K</given-names></name><name name-style="western"><surname>Bianchi</surname><given-names>GV</given-names></name><name name-style="western"><surname>Esteva</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Martin</surname><given-names>M</given-names></name><name name-style="western"><surname>Nusch</surname><given-names>A</given-names></name><name name-style="western"><surname>Sonke</surname><given-names>GS</given-names></name><name name-style="western"><surname>De la Cruz-Merino</surname><given-names>L</given-names></name><name name-style="western"><surname>Beck</surname><given-names>JT</given-names></name><name name-style="western"><surname>Pivot</surname><given-names>X</given-names></name><name name-style="western"><surname>Sondhi</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chakravartty</surname><given-names>A</given-names></name><name name-style="western"><surname>Rodriguez-Lorenc</surname><given-names>K</given-names></name><name name-style="western"><surname>Taran</surname><given-names>T</given-names></name><name name-style="western"><surname>Jerusalem</surname><given-names>G</given-names></name></person-group><article-title>Overall survival with ribociclib plus fulvestrant in advanced breast Cancer</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><fpage>514</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1911149</pub-id><pub-id pub-id-type="pmid">31826360</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martin M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Sondhi M, Wang Y, Chakravartty A, Rodriguez-Lorenc K, Taran T, Jerusalem G (2020) Overall survival with ribociclib plus fulvestrant in advanced breast Cancer. N Engl J Med 382:514&#8211;524<pub-id pub-id-type="pmid">31826360</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1911149</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><mixed-citation publication-type="other">Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martin M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Vidam G, Wang Y, Rodriguez Lorenc K, Miller M, Taran T and G. Jerusalem. (2018) &#8216;Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-Negative advanced breast cancer: MONALEESA-3&#8217; J Clin Oncol:JCO2018789909<pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2018.78.9909</pub-id><pub-id pub-id-type="pmid">29860922</pub-id></mixed-citation></ref><ref id="CR36"><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sledge</surname><given-names>GW</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Toi</surname><given-names>M</given-names></name><name name-style="western"><surname>Neven</surname><given-names>P</given-names></name><name name-style="western"><surname>Sohn</surname><given-names>J</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>K</given-names></name><name name-style="western"><surname>Pivot</surname><given-names>X</given-names></name><name name-style="western"><surname>Burdaeva</surname><given-names>O</given-names></name><name name-style="western"><surname>Okera</surname><given-names>M</given-names></name><name name-style="western"><surname>Masuda</surname><given-names>N</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>PA</given-names></name><name name-style="western"><surname>Koh</surname><given-names>H</given-names></name><name name-style="western"><surname>Grischke</surname><given-names>EM</given-names></name><name name-style="western"><surname>Frenzel</surname><given-names>M</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Barriga</surname><given-names>S</given-names></name><name name-style="western"><surname>Smith</surname><given-names>IC</given-names></name><name name-style="western"><surname>Bourayou</surname><given-names>N</given-names></name><name name-style="western"><surname>Llombart-Cussac</surname><given-names>A</given-names></name></person-group><article-title>MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast Cancer who had progressed while receiving endocrine therapy</article-title><source>J Clin Oncol</source><year>2017</year><volume>35</volume><fpage>2875</fpage><lpage>2884</lpage><pub-id pub-id-type="doi">10.1200/JCO.2017.73.7585</pub-id><pub-id pub-id-type="pmid">28580882</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Sledge GW Jr., Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Frenzel M, Lin Y, Barriga S, Smith IC, Bourayou N, Llombart-Cussac A (2017) MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast Cancer who had progressed while receiving endocrine therapy J Clin Oncol 35:2875&#8211;2884<pub-id pub-id-type="pmid">28580882</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2017.73.7585</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><mixed-citation publication-type="other">Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im YH, Kuemmel S, El-Saghir N, Liu MC, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu YS (2018) Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7):a randomised phase 3 trial Lancet Oncol<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(18)30292-4</pub-id><pub-id pub-id-type="pmid">29804902</pub-id></mixed-citation></ref><ref id="CR38"><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turner</surname><given-names>NC</given-names></name><name name-style="western"><surname>Ro</surname><given-names>J</given-names></name><name name-style="western"><surname>Andre</surname><given-names>F</given-names></name><name name-style="western"><surname>Loi</surname><given-names>S</given-names></name><name name-style="western"><surname>Verma</surname><given-names>S</given-names></name><name name-style="western"><surname>Iwata</surname><given-names>H</given-names></name><name name-style="western"><surname>Harbeck</surname><given-names>N</given-names></name><name name-style="western"><surname>Loibl</surname><given-names>S</given-names></name><name name-style="western"><surname>Huang Bartlett</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>K</given-names></name><name name-style="western"><surname>Giorgetti</surname><given-names>C</given-names></name><name name-style="western"><surname>Randolph</surname><given-names>S</given-names></name><name name-style="western"><surname>Koehler</surname><given-names>M</given-names></name><name name-style="western"><surname>Cristofanilli</surname><given-names>M</given-names></name><collab>Paloma Study Group</collab></person-group><article-title>Palbociclib in Hormone-Receptor-Positive advanced breast Cancer</article-title><source>N Engl J Med</source><year>2015</year><volume>373</volume><fpage>209</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1505270</pub-id><pub-id pub-id-type="pmid">26030518</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M, Paloma study group (2015) palbociclib in hormone-receptor-positive advanced breast cancer N Engl J Med 373:209&#8211;219<pub-id pub-id-type="pmid">26030518</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1505270</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Witzel</surname><given-names>I</given-names></name><name name-style="western"><surname>Laakmann</surname><given-names>E</given-names></name><name name-style="western"><surname>Weide</surname><given-names>R</given-names></name><name name-style="western"><surname>Neunhoffer</surname><given-names>T</given-names></name><name name-style="western"><surname>Park-Simon</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>M</given-names></name><name name-style="western"><surname>Fasching</surname><given-names>PA</given-names></name><name name-style="western"><surname>Hesse</surname><given-names>T</given-names></name><name name-style="western"><surname>Polasik</surname><given-names>A</given-names></name><name name-style="western"><surname>Mohrmann</surname><given-names>S</given-names></name><name name-style="western"><surname>Wurschmidt</surname><given-names>F</given-names></name><name name-style="western"><surname>Schem</surname><given-names>C</given-names></name><name name-style="western"><surname>Bechtner</surname><given-names>C</given-names></name><name name-style="western"><surname>Wurstlein</surname><given-names>R</given-names></name><name name-style="western"><surname>Fehm</surname><given-names>T</given-names></name><name name-style="western"><surname>Mobus</surname><given-names>V</given-names></name><name name-style="western"><surname>Burchardi</surname><given-names>N</given-names></name><name name-style="western"><surname>Loibl</surname><given-names>S</given-names></name><name name-style="western"><surname>Muller</surname><given-names>V</given-names></name></person-group><article-title>Treatment and outcomes of patients in the brain metastases in breast Cancer network registry</article-title><source>Eur J Cancer</source><year>2018</year><volume>102</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2018.07.004</pub-id><pub-id pub-id-type="pmid">30099223</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Witzel I, Laakmann E, Weide R, Neunhoffer T, Park-Simon TJ, Schmidt M, Fasching PA, Hesse T, Polasik A, Mohrmann S, Wurschmidt F, Schem C, Bechtner C, Wurstlein R, Fehm T, Mobus V, Burchardi N, Loibl S, Muller V (2018) Treatment and outcomes of patients in the brain metastases in breast cancer network registry. Eur J Cancer 102:1&#8211;9<pub-id pub-id-type="pmid">30099223</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2018.07.004</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>